Jeil Pharma Q1 2026: Consol. Revenue -20%, Op. Profit -93%; Subsidiary Oncovic Strong

Consolidated revenue KRW 130.3B (-20.1% YoY), operating profit KRW 0.4B (-92.6%)
Consolidated net profit KRW 3.2B (-11.1%), separate net loss KRW 2.5B (swing to loss)
Subsidiary Oncovic: revenue KRW 23.0B (+151%), net profit KRW 6.4B (+242%)
Total borrowings KRW 94.8B (+4.3B), cash KRW 53.5B, net debt ratio 13.8% (improved)
All treasury shares (133,355) sold; no dividend
R&D expense KRW 14.4B (10.7% of revenue)
Pending lawsuit with claim amount KRW 2.77B

ADVERTISEMENT (250px+)